JUN 1 2 2009

Section 5 – 510(k) Summary

Applicant:

Anulex Technologies, Inc.

5600 Rowland Road, Suite 280

Minnetonka, MN 55343

Contact Person:

Rachel Kennedy

Senior Regulatory Affairs Manager

Telephone: 952.224.4034

Fax: 952.224.4040

e-mail: rkennedy@anulex.com

Date Prepared:

May 13, 2009

Trade Name:

XcloseTM Tissue Repair System

Product Classification

21 CFR §878.5000

and Code:

Class: II

Product Code: GAT

Predicate Device:

K062307 – Xclose Tissue Repair System

Device Description:

The modified XcloseTM Tissue Repair System consists of two (2) non-absorbable braided surgical 3-0 suture (Ultra High Molecular Weight Polyethylene, UHMWPE) and T-anchor (polyethylene terephthalate, PET) assemblies, connected together with a loop of green 2-0 suture (PET). The 2-0 suture loop is used to facilitate tightening, drawing the 3-0 suture/anchor assemblies together, thereby re-approximating the tissue. The suture components conform to USP requirements The construct is provided sterile and

preloaded on a disposable delivery instrument.

Intended Use:

The XcloseTM Tissue Repair System is indicated for use in soft tissue approximation for procedures such as general and orthopedic surgery.

Summary of Technological Characteristics:

The modifications to the Xclose Tissue Repair System were conducted in accordance with the Anulex Design Control System. Accordingly, the risk analysis identified necessary design

verification and validation activities. As a result of this analysis, tensile testing was performed to confirm compliance to USP suture

requirements.

Conclusion:

The modified Xclose TM Tissue Repair System is substantially equivalent to the original Xclose Tissue Repair System in regards to

the indications for use, technology and the basic operating

principle.





Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

JUN 1 2 2009

Anulex Technologies, Incorporated % Ms. Rachel Kennedy Senior Regulatory Affairs Manager 5600 Rowland Road, Suite 280 Minnetonka, Minnesota 55343

Re: K091432

Trade/Device Name: Xclose™ Tissue Repair System

Regulation Number: 21 CFR 878.5000

Regulation Name: Nonabsorbable Poly(ethylene terephthalate) Surgical Suture

Regulatory Class: II Product Code: GAT Dated: May 13, 2009 Received: May 14, 2009

Dear Ms. Kennedy:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing

Page 2-Ms. Rachel Kennedy

practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to

http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/cdrh/mdr/ for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Mark N. Melkerson

Sincerely your

Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

510(k) Number (if known):	K	•
Device Name: Xclose TM Tis	sue Repair System	
Indications for Use:		
The Xclose TM Tissue Repair procedures such as general a	System is indicated for nd orthopedic surgery	or use in soft tissue approximation for .

•		
		. •
	•	
Prescription Use X (Part 21 CFR 801 Subpa	art D) AND/OR	Over-The-Counter Use(21 CFR 807 Subpart C)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

(Division Sign-Off)

Division of Surgical, Orthopedic,

and Restorative Devices